WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
World Federation of Hemophilia shared on LinkedIn:
”The WFH has released new evidence-based guidelines on AAV gene therapy for hemophilia, covering eligibility, center readiness, infusion safety, and long-term monitoring.
A major step forward for people with bleedingdisorders.
Find out more”
The World Federation of Hemophilia (WFH) has released a new evidence-based clinical practice guideline focused on adeno-associated virus (AAV) gene therapy for people with hemophilia (PwH).
This marks the addition of a dedicated gene therapy section within the broader WFH Guidelines for the Management of Hemophilia.
The guideline offers practical, up-to-date recommendations to support clinicians and patients in navigating this rapidly advancing treatment landscape.
It aims to promote safe, informed, and equitable use of gene therapy across the global bleeding disorders community.
Stay updated with Hemostasis Today.
-
May 28, 2026, 12:17Astha Thakkar: Practical Approaches to Platelet Thresholds in ITP
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79